OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis): A prospective trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions.
A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities.
Autorzy:
Abraham JE; Department of Oncology, Addenbrooke's Hospital, University of Cambridge, Hills Road, Box 193, Cambridge, CB2 0QQ, UK. .; NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Box 277, Hills Road, Cambridge, CB2 0QQ, UK. .; Strangeways Research Laboratory, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK. .; Cambridge Breast Unit and Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ, UK. . Hiller L; Warwick Clinical Trials Unit, University of Warwick, Gibbet Hill Road, Coventry, CV4 7AL, UK. . Dorling L; Strangeways Research Laboratory, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK. . Vallier AL; Department of Oncology, Cambridge Cancer Trials Centre, Box 279 (S4), Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK. .; Cambridge Breast Unit and Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ, UK. . Dunn J; Warwick Clinical Trials Unit, University of Warwick, Gibbet Hill Road, Coventry, CV4 7AL, UK. . Bowden S; Cancer Research UK Clinical Trials Unit, Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK. . Ingle S; Department of Oncology, Addenbrooke's Hospital, University of Cambridge, Hills Road, Box 193, Cambridge, CB2 0QQ, UK. .; NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Box 277, Hills Road, Cambridge, CB2 0QQ, UK. .; Department of Oncology, Cambridge Cancer Trials Centre, Box 279 (S4), Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK. . Jones L; Department of Oncology, Addenbrooke's Hospital, University of Cambridge, Hills Road, Box 193, Cambridge, CB2 0QQ, UK. .; NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Box 277, Hills Road, Cambridge, CB2 0QQ, UK. .; Cambridge Breast Unit and Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ, UK. . Hardy R; Department of Oncology, Addenbrooke's Hospital, University of Cambridge, Hills Road, Box 193, Cambridge, CB2 0QQ, UK. .; NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Box 277, Hills Road, Cambridge, CB2 0QQ, UK. .; Department of Oncology, Cambridge Cancer Trials Centre, Box 279 (S4), Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK. . Twelves C; Level 4, Leeds Institute of Cancer and Pathology and Leeds Experimental Cancer Medical Centre, St James Institute of Oncology, Beckett Street, Leeds, LS9 7TF, UK. . Poole CJ; Warwick Clinical Trials Unit, University of Warwick, Gibbet Hill Road, Coventry, CV4 7AL, UK. . Pharoah PD; Strangeways Research Laboratory, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK. . Caldas C; Department of Oncology, Addenbrooke's Hospital, University of Cambridge, Hills Road, Box 193, Cambridge, CB2 0QQ, UK. .; NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Box 277, Hills Road, Cambridge, CB2 0QQ, UK. .; Cambridge Breast Unit and Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ, UK. .; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK. . Earl HM; Department of Oncology, Addenbrooke's Hospital, University of Cambridge, Hills Road, Box 193, Cambridge, CB2 0QQ, UK. .; NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Box 277, Hills Road, Cambridge, CB2 0QQ, UK. .; Cambridge Breast Unit and Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ, UK. .
Pokaż więcej
Źródło:
BMC medicine [BMC Med] 2015 Dec 29; Vol. 13, pp. 306. Date of Electronic Publication: 2015 Dec 29.
A Bayesian adaptive design for biomarker trials with linked treatments.
Autorzy:
Wason JM; MRC Biostatistics Unit Hub for Trials Methodology Research, Cambridge, UK. Abraham JE; Department of Oncology, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cambridge, UK.; Cambridge Breast Unit, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK.; Cambridge Experimental Cancer Medicine Centre, Cambridge, UK. Baird RD; Department of Oncology, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cambridge, UK.; Cambridge Breast Unit, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK.; Cambridge Experimental Cancer Medicine Centre, Cambridge, UK. Gournaris I; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK. Vallier AL; Cambridge Breast Unit, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK. Brenton JD; Department of Oncology, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cambridge, UK.; Cambridge Experimental Cancer Medicine Centre, Cambridge, UK.; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK. Earl HM; Department of Oncology, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cambridge, UK.; Cambridge Breast Unit, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK.; Cambridge Experimental Cancer Medicine Centre, Cambridge, UK. Mander AP; MRC Biostatistics Unit Hub for Trials Methodology Research, Cambridge, UK.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2015 Sep 01; Vol. 113 (5), pp. 699-705. Date of Electronic Publication: 2015 Aug 11.
Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis.
Autorzy:
Schwarz RF; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom. Ng CK; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom; Department of Oncology, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, United Kingdom. Cooke SL; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom. Newman S; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom. Temple J; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom. Piskorz AM; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom. Gale D; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom. Sayal K; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom. Murtaza M; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom. Baldwin PJ; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom. Rosenfeld N; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom; Department of Oncology, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, United Kingdom. Earl HM; Department of Oncology, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom. Sala E; University Department of Radiology, Addenbrooke's Hospital, Cambridge, United Kingdom. Jimenez-Linan M; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom. Parkinson CA; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom; Department of Oncology, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, United Kingdom. Markowetz F; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom; Department of Oncology, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, United Kingdom. Brenton JD; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom; Department of Oncology, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, United Kingdom.
Pokaż więcej
Źródło:
PLoS medicine [PLoS Med] 2015 Feb 24; Vol. 12 (2), pp. e1001789. Date of Electronic Publication: 2015 Feb 24 (Print Publication: 2015).
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies